Stock Events

Stock Events

ProKidney 

$2.09
38
+$0+0% Today

Statistics

Day High
2.16
Day Low
2.07
52W High
5.18
52W Low
0.57
Volume
23,109
Avg. Volume
-
Mkt Cap
295.83M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.16
-0.15
-0.13
-0.12
Expected EPS
-0.137983
Actual EPS
N/A

Financials

-80,507.89%Profit Margin
Unprofitable
2021
2022
2023
2024
152,000Revenue
-122.37MNet Income

Analyst Ratings

12Average Price Target
The highest estimate is 12.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PROK. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap112.22B
Vertex Pharmaceuticals is developing treatments for kidney diseases, including APOL1-mediated kidney diseases, which could compete with ProKidney's regenerative medicine approach.
Aurinia Pharmaceuticals
AUPH
Mkt Cap2.13B
Aurinia Pharmaceuticals focuses on the development of therapies for kidney diseases, including lupus nephritis, potentially competing in the kidney treatment space.
Akebia Therapeutics
AKBA
Mkt Cap376.37M
Akebia Therapeutics focuses on kidney disease treatments, including anemia caused by chronic kidney disease, making it a direct competitor.
Novartis
NVS
Mkt Cap293.34B
Novartis offers a broad portfolio of drugs, including those for kidney conditions, competing on a wide front in the kidney treatment market.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.51B
BioMarin Pharmaceutical develops therapies for genetic diseases, some of which may involve kidney function, placing it as a potential competitor in the broader market for kidney-related treatments.
Pfizer
PFE
Mkt Cap156.77B
Pfizer has a diverse portfolio that includes treatments for kidney cancer and other kidney-related conditions, making it a competitor in the kidney health market.
Johnson & Johnson
JNJ
Mkt Cap564.35B
Johnson & Johnson, through its pharmaceutical division Janssen, offers medications for chronic kidney disease and complications, competing in the kidney treatment landscape.

About

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Show more...
CEO
Dr. Bruce Culleton M.D.
Employees
204
Country
Cayman Islands
ISIN
US74291D1046

Listings

XNAS
US
PROK
BOATS
BOATS
PROK.BOATS

0 Comments

Share your thoughts

FAQ

What is ProKidney stock price today?▼
The current price of PROK is $2.09 USD — it has increased by +0% in the past 24 hours. Watch ProKidney stock price performance more closely on the chart.
What is ProKidney stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ProKidney stocks are traded under the ticker PROK.
Is ProKidney stock price growing?▼
PROK stock has risen by +3.72% compared to the previous week, the month change is a +8.29% rise, over the last year ProKidney has showed a +179% increase.
What is ProKidney market cap?▼
Today ProKidney has the market capitalization of 295.83M
When is the next ProKidney earnings date?▼
ProKidney is going to release the next earnings report on May 08, 2026.
What were ProKidney earnings last quarter?▼
PROK earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.15 USD resulting in a +4.53% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ProKidney revenue for the last year?▼
ProKidney revenue for the last year amounts to 152,000 USD.
What is ProKidney net income for the last year?▼
PROK net income for the last year is -122.37M USD.
How many employees does ProKidney have?▼
As of April 22, 2026, the company has 204 employees.
In which sector is ProKidney located?▼
ProKidney operates in the Health & Wellness sector.
When did ProKidney complete a stock split?▼
ProKidney has not had any recent stock splits.
Where is ProKidney headquartered?▼
ProKidney is headquartered in Winston-Salem, Cayman Islands.